| Literature DB >> 16367757 |
Tanja Fauti1, Sabine Müller-Brüsselbach, Mihaela Kreutzer, Markus Rieck, Wolfgang Meissner, Ulf Rapp, Horst Schweer, Martin Kömhoff, Rolf Müller.
Abstract
A role for the nuclear receptor peroxisome proliferator-activated receptor-beta (PPARbeta) in oncogenesis has been suggested by a number of observations but its precise role remains elusive. Prostaglandin I2 (PGI2, prostacyclin), a major arachidonic acid (AA) derived cyclooxygenase (Cox) product, has been proposed as a PPARbeta agonist. Here, we show that the 4-hydroxytamoxifen (4-OHT) mediated activation of a C-Raf-estrogen receptor fusion protein leads to the induction of both the PPARbeta and Cox-2 genes, concomitant with a dramatic increase in PGI2 synthesis. Surprisingly, however, 4-OHT failed to activate PPARbeta transcriptional activity, indicating that PGI2 is insufficient for PPARbeta activation. In agreement with this conclusion, the overexpression of ectopic Cox-2 and PGI2 synthase (PGIS) resulted in massive PGI2 synthesis but did not activate the transcriptional activity of PPARbeta. Conversely, inhibition of PGIS blocked PGI2 synthesis but did not affect the AA mediated activation of PPARbeta. Our data obtained with four different cell types and different experimental strategies do not support the prevailing opinion that PGI2 plays a significant role in the regulation of PPARbeta.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16367757 DOI: 10.1111/j.1742-4658.2005.05055.x
Source DB: PubMed Journal: FEBS J ISSN: 1742-464X Impact factor: 5.542